ClinicalTrials.gg
RecruitingNCT07416747SWINGUpdated Oct 7, 2026

GynMDD Add-On to Supportive Psychotherapy in Mild to Moderate Depression

An interventional study of GynMDD and Placebo in Depression, Depression Disorder and Depression in Adults, sponsored by Fondation FondaMental. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Fondation FondaMental · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 7, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 266 studies in Depression with a site in France — 63 open to participants now, 67 under way, 2 of them phase 3. Depression · France.

Planned enrollment
69th of 185
168 · median 120
Started
2026
with 16 others
No phase
133 of 266
43 open now
Primary completion
2027-11
later than 42 of 66 live
Registered
250th of 266
by date

Among the 266 studies in Depression with a site in France, this one is the 69th largest by planned enrollment of the 185 interventional ones that give a count, is one of 17 that started in 2026, is one of 133 with no phase, reaches primary completion later than 42 of the 66 other live ones, and was the 250th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

63 of the 266 studies in Depression with a site in France are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Depression with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether the dietary supplement GynMDD, when taken as an add-on to supportive psychotherapy, can improve symptoms of mild to moderate depression in adults aged 18 to 65. The main questions it aims to answer are:

Does adding GynMDD to supportive psychotherapy lead to a greater reduction in depressive symptoms (measured by the MADRS scale) compared with supportive psychotherapy plus placebo?

Does the supplement also improve digestive well-being and influence gut microbiota profiles over the course of treatment?

Researchers will compare patients receiving supportive psychotherapy + GynMDD to those receiving supportive psychotherapy + placebo to see if GynMDD provides additional benefits beyond standard care.

Participants will:

  • Attend regular appointments with their general practitioner
  • Complete one supportive psychotherapy session per week for 8 weeks
  • Take a daily dose of GynMDD or placebo
  • Complete weekly self-assessment questionnaires on mood, digestive symptoms, and any side effects via a mobile app
  • Provide two stool samples (at the start and end of the study) for microbiota analysis
03

Conditions studied

  • Depression
  • Depression Disorder
  • Depression in Adults

Keywords

  • Gut-Brain Axis
  • Gut Microbiota
  • GynMDD
  • Mild Depression
  • Moderate Depression
  • MADRS
  • Supportive Psychotherapy
  • Psychotherapy
  • Dietary Supplement
  • Probiotic Supplement
  • Real-World Study
  • Mental Health
  • Curcumin
  • L-Glutamine
  • Randomized Controlled Trial
  • PHQ-9
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 65 years, inclusive
  • The main reason for consultation is a suspected depressive episode
  • MADRS score between 15 and 34, indicating mild to moderate depression
  • No suicidal risk, defined as a score of 0 on item 10 of the MADRS scale
  • (BMI) between 19 and 29 (inclusive)
  • Signed , confirming that the participant understands the purpose and requirements of the study and agrees to comply with the procedures (including scheduled supportive psychotherapy sessions)
  • Affiliation with the French national health insurance system or beneficiary of such coverage

Exclusion criteria

Exclusion Criteria:

  • History of severe psychiatric disorders or currently undergoing supportive psychotherapy
  • Confirmed suicidal risk, defined as a score between 1 and 6 on MADRS item 10
  • Current treatment with antidepressants (AD)
  • MADRS score > 34
  • Conditions in which probiotic administration is not recommended (e.g., immunodeficiency, presence of a venous catheter)
  • Allergy to any component of the placebo or the GynMDD dietary supplement
  • Current consumption of probiotic-based dietary supplements
  • Recent infectious episodes that may require antibiotic therapy
  • Current treatment with anxiolytics
  • Long-term chronic anti-inflammatory treatment
  • Alcohol abuse, defined as a consumption of 10 standard drinks per week or more
  • Use of illicit drugs or substances of abuse
  • Inability to provide
  • Participation in another clinical study within the past 12 months
  • Pregnant or breastfeeding women
  • Patients without health insurance
  • Individuals under legal protection, guardianship, trusteeship, or any other protective measure
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
168 participants (estimated)

Study arms

  • Experimental
    Supportive Psychotherapy + GynMDD

    Supportive Psychotherapy and Dietary Supplement

    Dietary Supplement: GynMDD

  • Placebo comparator
    Supportive Psychotherapy + Placebo

    Supportive Psychotherapy and Placebo

    Other: Placebo

Interventions

  • Dietary supplementGynMDD

    Dietary Supplement: GynMDD (Sorolys®) Daily 2.5 g stick for 8 weeks Includes L-glutamine, Cavacurmin®, and Lacticaseibacillus rhamnosus GG

  • OtherPlacebo

    Placebo for 8 weeks Identical stick without active ingredients; β-carotene added for color

06

What researchers measure

Primary outcomes

  1. Change in MADRS Score

    Assessment of depressive symptoms using the Montgomery-Åsberg Depression Rating Scale (MADRS).

    Time frame: Baseline (V0) to Week 8 (V2)

Secondary outcomes

  1. Change in Digestive Symptom Score (WGO scale)

    Difference in scores on the World Gastroenterology Organization digestive health scale between baseline and follow-up visits.

    Time frame: Baseline (V0), Week 4 (V1), Week 8 (V2)

  2. Change in PHQ-9 Self-Reported Depression Score

    Weekly PHQ-9 scores completed by participants through the digital platform to assess changes in depressive symptoms.

    Time frame: Weekly for 8 weeks

  3. Change in GSRS-IBS Digestive Symptom Score

    Weekly GSRS-IBS digestive symptom scores completed on the digital platform.

    Time frame: Weekly for 8 weeks

  4. Fecal Microbiota Metagenomic Profile (Shotgun Sequencing)

    Presence of predictive microbiota signatures and evolution of gut microbiome composition.

    Time frame: Baseline (V0) and Week 8 (V2)

  5. Adverse Events Reporting

    Time frame: Weekly until 8 week and at Week 4 (V1), Week 8 (V2)

  6. Proportion of participants requiring initiation of antidepressant therapy

    Time frame: Up to Week 8 (V2)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Nov 2027, 20 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 20 months is close to that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2025
First posted
Feb 18, 2026
StartActual
Mar 24, 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 7, 2026
Sites
Hôpital Albert Chenevier 40 rue de Mesly is now Recruiting
Oct 7, 2026
Contact
Study contact changed: i•••@fondation-fondamental.org→f•••@fondation-fondamental.org; l•••@fondation-fondamental.org→m•••@fondation-fondamental.org. See the current contact
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Not yet recruiting→Recruiting
    Hôpital Albert Chenevier 40 rue de Mesly is now Recruiting
    Contact Study contact changed: i•••@fondation-fondamental.org→f•••@fondation-fondamental.org; l•••@fondation-fondamental.org→m•••@fondation-fondamental.org. See the current contact
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07416747
Lead sponsor
Fondation FondaMental
Collaborators
GYNOV
Responsible party
Sponsor
First posted
Feb 18, 2026
Start date
Mar 24, 2026
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Clinical Project Manager
Contact
michelle.haddad@fondation-fondamental.org
+3314981326
Clinical Operation Director
Contact
florence.mahe@fondation-fondamental.org
Marion LEBOYER, Pr
study chair · Fondation FondaMental
FAUCHER Pierre, Dr
study director · GYNOV

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion